PIK3CA and cholangiocarcinoma: These findings provide early clinical evidence that alpelisib has a manageable safety profile and meaningful efficacy in pretreated PIK3CA-mutant CC, supporting its further development as a targeted therapy for this molecularly defined subgroup.